Evidence map›Paper›PMID 40805125›Full record

ArticleCancers2025

Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer Using Pre-Treatment Histopathologic Images.

Hikmat Khan, Ziyu Su, Huina Zhang, Yihong Wang, Bohan Ning, Shi Wei, Hua Guo, Zaibo Li, Muhammad Khalid Khan Niazi

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Hikmat KhanDepartment of Pathology, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.ORCID 0009-0008-2550-1991
Ziyu SuDepartment of Pathology, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.
Huina ZhangDepartment of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0000-0002-4208-7680
Yihong WangDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Lifespan Academic Medical Center, Providence, RI 02903, USA.
Bohan NingDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Shi WeiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-4417-593X
Hua GuoDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Zaibo LiDepartment of Pathology, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-1325-1696
Muhammad Khalid Khan NiaziDepartment of Pathology, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.

Funding

An ensemble deep learning model for tumor bud detection and risk stratification in colorectal carcinoma.R01CA276301 · NCI · OHIO STATE UNIVERSITY · PI Wei Chen, Muhammad Khalid Khan Niazi · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA276301NIH HHS 1R01CA276301-01
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) remains a major clinical challenge due to its aggressive behavior and lack of targeted therapies. Accurate early prediction of response to neoadjuvant chemotherapy (NACT) is essential for guiding personalized treatment strategies and improving patient outcomes. In this study, we present an attention-based multiple instance learning (MIL) framework designed to predict pathologic complete response (pCR) directly from pre-treatment hematoxylin and eosin (H&E)-stained biopsy slides. The model was trained on a retrospective in-house cohort of 174 TNBC patients and externally validated on an independent cohort (n = 30). It achieved a mean area under the curve (AUC) of 0.85 during five-fold cross-validation and 0.78 on external testing, demonstrating robust predictive performance and generalizability. To enhance model interpretability, attention maps were spatially co-registered with multiplex immunohistochemistry (mIHC) data stained for PD-L1, CD8+ T cells, and CD163+ macrophages. The attention regions exhibited moderate spatial overlap with immune-enriched areas, with mean Intersection over Union (IoU) scores of 0.47 for PD-L1, 0.45 for CD8+ T cells, and 0.46 for CD163+ macrophages. The presence of these biomarkers in high-attention regions supports their biological relevance to NACT response in TNBC. This not only improves model interpretability but may also inform future efforts to identify clinically actionable histological biomarkers directly from H&E-stained biopsy slides, further supporting the utility of this approach for accurate NACT response prediction and advancing precision oncology in TNBC.

Indexed as

artificial intelligence (AI)neoadjuvant chemotherapy (NACT)pathologic complete response (pCR)treatment response predictiontriple-negative breast cancer (TNBC)

Identifiers

PMID40805125
PMCPMC12346615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.